Difference between revisions of "CERNA3"
Jiabao Cao (talk | contribs) |
|||
| Line 4: | Line 4: | ||
CERNA3:competing endogenous lncRNA 3 for miR-645 | CERNA3:competing endogenous lncRNA 3 for miR-645 | ||
| − | CTA<ref name="ref1" /> | + | CTA <ref name="ref1" /> |
| − | |||
| + | ===Function=== | ||
| + | LncRNA CTA is an essential regulator in DOX-induced (doxorubicin) osteosarcoma cell apoptosis, and the lncRNA CTA-miR-210 interaction plays an important role in reducing osteosarcoma chemoresistance <ref name="ref1" />. Overexpression of lncRNA CTA markedly enhances DOX-induced apoptosis and inhibition of proliferation in osteosarcoma cells, MG63 and Saos-2 cells. Moreover, lncRNA CTA exerts a synergic effect with DOX in increasing the levels of Caspase 3 and in decreasing the levels of Bcl-2 and in growth inhibition of osteosarcoma cells in nude mice <ref name="ref1" />. | ||
| + | |||
| + | Low expression of lncRNA CTA is significantly associated with the advanced clinical stage, tumor size and the malignant progression of osteosarcoma, and patients with low lncRNA CTA expression show a worse prognosis when compared with those with high level of lncRNA CTA <ref name="ref1" />. | ||
| − | |||
| − | |||
| − | |||
| − | |||
===Regulation=== | ===Regulation=== | ||
| − | Chronic exposure to DOX induces significant downregulation of CTA in osteosarcoma MG63/DOX cells compared with their parental cells | + | Chronic exposure to DOX induces significant downregulation of CTA in osteosarcoma MG63/DOX cells compared with their parental cells, and bioinformatic analysis shows that lncRNA CTA is a direct target of miR-21 <ref name="ref1" />. |
| − | + | ||
| + | ===Expression=== | ||
| + | CTA's expression is significantly decreased in osteosarcoma tumor tissues compared with adjacent tissues <ref name="ref1" />. | ||
| + | |||
===Diseases=== | ===Diseases=== | ||
| − | Osteosarcoma<ref name="ref1" /> | + | Osteosarcoma <ref name="ref1" /> |
| − | + | ||
| − | |||
===Sequence=== | ===Sequence=== | ||
>XR_001745918.1 PREDICTED: Homo sapiens uncharacterized LOC105375847 (LOC105375847), transcript variant X1, ncRNA | >XR_001745918.1 PREDICTED: Homo sapiens uncharacterized LOC105375847 (LOC105375847), transcript variant X1, ncRNA | ||
Latest revision as of 02:48, 29 August 2017
Contents
Annotated Information
Name
CERNA3:competing endogenous lncRNA 3 for miR-645
CTA [1]
Function
LncRNA CTA is an essential regulator in DOX-induced (doxorubicin) osteosarcoma cell apoptosis, and the lncRNA CTA-miR-210 interaction plays an important role in reducing osteosarcoma chemoresistance [1]. Overexpression of lncRNA CTA markedly enhances DOX-induced apoptosis and inhibition of proliferation in osteosarcoma cells, MG63 and Saos-2 cells. Moreover, lncRNA CTA exerts a synergic effect with DOX in increasing the levels of Caspase 3 and in decreasing the levels of Bcl-2 and in growth inhibition of osteosarcoma cells in nude mice [1].
Low expression of lncRNA CTA is significantly associated with the advanced clinical stage, tumor size and the malignant progression of osteosarcoma, and patients with low lncRNA CTA expression show a worse prognosis when compared with those with high level of lncRNA CTA [1].
Regulation
Chronic exposure to DOX induces significant downregulation of CTA in osteosarcoma MG63/DOX cells compared with their parental cells, and bioinformatic analysis shows that lncRNA CTA is a direct target of miR-21 [1].
Expression
CTA's expression is significantly decreased in osteosarcoma tumor tissues compared with adjacent tissues [1].
Diseases
Osteosarcoma [1]
Sequence
>XR_001745918.1 PREDICTED: Homo sapiens uncharacterized LOC105375847 (LOC105375847), transcript variant X1, ncRNA
000081 CGGAGGAGCC GAAGTCCCGC AGGGTGGGGT CCCCGCCTGC GCCGAGAGGG CCACCTGGTC GAGAGAACAG GCGACACGGA 000160
000161 AACCTGAGAA ACTCCTCTGT CTGGTGCACC TAACCCTCTT CCTCATAAAG TGCACACGAA CTCTGGTTTT TCCGTTGCAA 000240
000241 ATTTTGCTTT CTACATAGAC CATACCATTC GTTGCTCTCT GAGGATGAGC TCCTGGCTTC CCAGTCCAGC AGAAGTATCT 000320
000321 ACATCTATTT CTGGAAAGGA CCTGAACTTG GCTTCTCGTC CTTCTGGAAA GTGAGGCGAA AATGCCAGGC TGCGCAGCTA 000400
000401 TCCTGAGGCC CGGCCTGGAA CCTGGCTAGC CACCCAGTCC TGATACCTCA TCTCCTTTCT GTTGGATAAA GTCATTGGAT 000480
000481 AAGATCCCCC AGGGTCTTCT TAATACTGAA CATCTGTTCA TAATCACATA AGTGACCAAG TATAGTGGAA AACCCGAATG 000560
000561 GTCAACTGAG CTGAGCAGTG GGAGAGAGCG CAGGGCTTAC CTCATCCTTT AAGTATTTGA GGAACTGGTG AACAAGTTAA 000640
000641 CTACTTTGAT AGTAAACGAG GAAATTTCTT TATAGAGAAA AGCAAAATGT GGCCCAGCAG GTATGTGAAA AATGGCTGAT 000720
000721 GTGACTAGAA CTAAGGAAAC AAATGGTTAA GATAATATTA GACAAAAGTA ATGGAAATTT TTTTTTTTTG GAAAACAGTA 000800
000801 TGGAGGGTCC TCAAAAAAT
Labs working on this lncRNA
- Department of Orthopaedics, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China.
